Leo B. Pavliv
Net Worth

Last updated:

What is Leo B. Pavliv net worth?

The estimated net worth of Mr. Leo B. Pavliv is at least $7,936,924 as of 18 Mar 2013. He owns shares worth $83,037 as insider, has earned $10,047 from insider trading and has received compensation worth at least $7,843,840 in Cumberland Pharmaceuticals Inc..

What is the salary of Leo B. Pavliv?

Mr. Leo B. Pavliv salary is $490,240 per year as Executive Vice President of Operations & Chief Devel. Officer in Cumberland Pharmaceuticals Inc..

How old is Leo B. Pavliv?

Mr. Leo B. Pavliv is 64 years old, born in 1961.

What stocks does Leo B. Pavliv currently own?

As insider, Mr. Leo B. Pavliv owns shares in one company:

Company Title Shares Price per share Total value
Cumberland Pharmaceuticals Inc. (CPIX) Executive Vice President of Operations & Chief Devel. Officer 26,445 $3.14 $83,037

What does Cumberland Pharmaceuticals Inc. do?

Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, rheumatology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of chronic and acute constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections. It also develops RediTrex injection for the treatment of active rheumatoid, juvenile idiopathic, and severe psoriatic arthritis, as well as disabling psoriasis. In addition, the company is developing ifetroban, a product candidate that is in phase II clinical trial for the treatment of aspirin-exacerbated respiratory disease, systemic sclerosis, and duchenne muscular dystrophy; and has completed phase II clinical trial for the treatment of hepatorenal syndrome and portal hypertension. Further, it develops a clinical program for the use of ifetroban to treat progressive fibrosing interstitial lung diseases; and a product candidate that is in Phase II clinical trial for cholesterol reducing agent to use in the hospital setting. The company was incorporated in 1999 and is headquartered in Nashville, Tennessee.

Leo B. Pavliv insider trading

Cumberland Pharmaceuticals Inc.

Mr. Leo B. Pavliv has made only one insider trade between 2009-2013, according to the Form 4 filled with the SEC.

As of 18 Mar 2013 he still owns at least 26,445 units of CPIX stock.

Transaction Date Security Shares Price per share Total value Source
Option
Common stock 160,000 $3.5 $560,000
Option
Options 160,000 $3.5 $560,000
Option
Common stock 3,000 $1.63 $4,890
Option
Options 3,000 $1.63 $4,890
Sale
Common stock 1,700 $5.91 $10,047
Purchase
Common stock 5,000 $6.78 $33,880
Option
Common stock 18,000 $0.93 $16,650
Option
Options 18,000 $0.93 $16,650
Option
Options 5,000 $0.5 $2,500
Option
Common stock 5,000 $0.5 $2,500

Cumberland Pharmaceuticals key executives

Cumberland Pharmaceuticals Inc. executives and other stock owners filed with the SEC: